Pneumococcal seroepidemiology in Turkey: implications for vaccine coverage.
This article [corrected] aims to bring up the most prevalent pneumococcal serotypes and serogroups detected in recent Turkish studies. The current PCV-7 formulation covers only 38.3% [corrected] of IPI in Turkey and if serotypes/groups 4, 9V and [corrected] 18C in the current formulation are replaced with 1, 3 [corrected] and 9A in PCV-7, then the vaccination coverage will increase up to 64.2% [corrected] an improvement that is significant statistically. Similarly, if 11A, 12F, 15B, 22F and 33F [corrected] are substituted with 6A, 9A, 9L, 19C and 23B in existing PPV-23, the new formulation will increase coverage up to 91.2% [corrected] for Turkish population.
Erdem
Hakan
H
Sener
Burcin
B
D002353:Carrier State; D019538:Health Care Surveys; D006801:Humans; D008070:Lipopolysaccharides / Q000276:immunology; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000276:immunology / Q000627:therapeutic use*; D014421:Turkey / Q000453:epidemiology
D008070:Lipopolysaccharides; D022242:Pneumococcal Vaccines